Just a little over a year after being spun out of a Roche acquisition target, the fledgling UK biotech, Black Belt TX Ltd., says it will form a strategic partnership with an early-stage US firm, Praxis Biotech, on developing anticancer drugs which modulate cellular stress response pathways in the tumor microenvironment, potentially a new mode of action.
It is one of the first collaborations entered into by Black Belt TX, a biotech set up with the backing of the Belgian venture capital firm, DROIA Oncology Ventures, which also backed Tusk Therapeutics Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?